WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today announced the appointment of Co-Founder Kimberly Noonan, PhD, MPH, to Executive Vice President, Chief Science & Technology Officer. In this role, Dr. Noonan’s leadership will expand to include WindMIL’s efforts in manufacturing and manufacturing science and technology (MS&T).